Tango Therapeutics, Inc.
NASDAQ:TNGXBiotechnology
-$3.24 today
- Market cap
- $3.71B
- Beta
- 1.19
- P/E (TTM)
- -38.9
- EPS (TTM)
- -$0.75
Volume 2.75M
Average 3.67M
TNGX Total Current Liabilities
All obligations due within one year.
Tango Therapeutics, Inc.NASDAQ: TNGX
Total Current Liabilities · Q3 FY2026 · quarter ended Sep 2026
Total current liabilities rises 36.4% from a year ago
Total current liabilities stood at $25.16M at the end of Q3 FY2026, up 36.4% from a year earlier and up 24.0% from the prior quarter. Over 3 fiscal years it compounded at -26.9% a year.
Context
- Total current liabilities amounted to 2.4% of total assets at the end of Q3 FY2026, down 6.3 pp from a year earlier.
- Total current liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +36.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 21.68M USD
- Year-over-year change
- -43.2%
- 4-year CAGR
- -14.6%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 21.68M | -43.2% |
| FY2024 | 2024-12-31 | 38.17M | -16.9% |
| FY2023 | 2023-12-31 | 45.94M | -17.3% |
| FY2022 | 2022-12-31 | 55.55M | +36.5% |
| FY2021 | 2021-12-31 | 40.69M | — |
Total Current Liabilities vs competitors
How TNGX compares with its peers on the latest reported figures
- TNGX's Sep 2026 total current liabilities of $25.16M is the 10th highest of the 11 companies compared; the peer median is $57.6M.
- Its year-over-year change of +36.4% is the 6th highest of 11, against a peer median of +42.0%.
- Total current liabilities amounts to 2.4% of total assets for TNGX, versus a peer median of 9.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $354.06M | +91.9% | +67.3% | 8.2% | |
| Aug 2026 | $130.74M | +58.8% | +7.0% | 10.9% | |
| Jun 2026 | $86.76M | +30.7% | +84.2% | 11.7% | |
| Mar 2026 | $64.83M | +27.5% | +22.9% | 6.3% | |
| Mar 2026 | $64.4M | -9.7% | +2.7% | 29.0% | |
| Jun 2026 | $50.8M | +56.2% | -26.2% | 5.3% | |
| Sep 2026 | $43.99M | +53.2% | -16.3% | 4.4% | |
| Mar 2026 | $41.72M | +110.8% | +34.7% | 34.9% | |
| Mar 2026 | $27.25M | -33.2% | -9.5% | 8.3% | |
| Sep 2026 | $25.16M | +36.4% | -26.9% | 2.4% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $11.05M | -18.4% | +34.0% | 10.3% |
| Peer median (excluding TNGX) | $57.6M | +42.0% | +14.9% | 9.3% | |
Competitors are the stored peer set for TNGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 142.75M | 59.97M | 66.39M | 69.53M | 112.28M |
| Short-term Investments | 342.51M | 306.17M | 270.5M | 188.39M | 230.86M |
| Net Receivables | 2M | 2M | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 567K | 7.14M | 9.65M | 8.43M | 10.62M |
| Total Current Assets | 492.34M | 375.27M | 346.54M | 266.34M | 353.76M |
| Property, Plant & Equipment (Net) | 6.09M | 57.77M | 53.42M | 47.58M | 42.49M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.73M | 3.43M | 2.61M | 2.57M | 2.44M |
| Total Non-current Assets | 7.82M | 61.2M | 56.03M | 50.15M | 44.93M |
| Total Assets | 500.16M | 436.47M | 402.57M | 316.49M | 398.69M |
| Account Payables | 3.23M | 4.45M | 2.79M | 1.6M | 1.18M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 52K | 35K | 0 | 0 | 0 |
| Deferred Revenue | 26.02M | 31.79M | 25.67M | 17.62M | 0 |
| Other Current Liabilities | 666K | 1.27M | 7.49M | 1.74M | 1.29M |
| Total Current Liabilities | 40.69M | 55.55M | 45.94M | 38.17M | 21.68M |
| Long-term Debt | 0 | 0 | 0 | 0 | 30.83M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 114.72M | 92.09M | 66.68M | 44.77M | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 114.72M | 131.45M | 103.52M | 78.81M | 30.83M |
| Total Liabilities | 155.41M | 186.99M | 149.46M | 116.98M | 52.51M |
| Common Stock | 88K | 88K | 102K | 108K | 136K |
| Retained Earnings | (161.34M) | (269.51M) | (371.26M) | (501.56M) | (603.15M) |
| Accumulated OCI | (765K) | (3.71M) | 186K | 336K | 224K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 344.75M | 249.48M | 253.11M | 199.52M | 346.18M |
| Total Debt | 1.5M | 41.13M | 38.92M | 36.49M | 33.57M |
| Net Debt | (141.24M) | (18.84M) | (27.47M) | (33.04M) | (78.71M) |
Tango Therapeutics, Inc.
NASDAQ:TNGX
Intrinsic Alpha fair value
Locked
Current Price
$21.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.